TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical
company developing targeted therapies for the treatment of cancer and
hepatitis C virus infection (HCV), today announced that the following
preclinical abstracts will be the subject of oral and poster presentations
at the 2008 Annual Meeting of the American Association for Cancer Research
(AACR), being held April 12-16, 2008 in San Diego:
-- "Targeting mutant p53 protein and tumor vasculature: An effective
combination therapy for advanced breast tumors" (Abstract #2341, New
Targets 1: Mechanisms Session) - Poster session scheduled for Monday,
April 14, 2008 from 8:00 am to 12:00 pm.
-- "An immunocytokine that binds to phosphatidylserine generates an
effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor
Vaccines Session) - Poster session scheduled for Monday, April 14,
2008 from 1:00 pm to 5:00 pm.
-- "Combination of a monoclonal anti-phosphatidylserine antibody with
docetaxel strongly inhibits the growth and metastasis of
hormone-refractory prostate cancers in mice" (Abstract #2551, New
Approaches to Biological Therapy Session) - Oral presentation
scheduled for Monday, April 14, 2008 at 2:10 pm.
-- "Antibody targeting of phosphatidylserine produces a cytokine
microenvironment that enhances innate anti-tumor immune responses"
(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics
Session) - Poster session scheduled for Tuesday, April 15, 2008 from
8:00 am to 12:00 pm.
Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative product candidates in clinical trials for the
treatment of cancer and hepatitis C virus (HCV) infection. The company is
pursuing three separate clinical programs in cancer and HCV infection with
its lead product candidates bavituximab and Cotara(R). Peregrine also has
in-house manufacturing capabilities through its wholly owned subsidiary
Avid Bioservices, Inc. (http://www.avidbio.com), which provides development
and bio-manufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
GendeLLindheim BioCom Partners
email@example.com Barbara Lindheim
(800) 987-8256 (212) 918-4650
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved